false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Onconep ...
Plasma Cell Dyscrasias and Engineered Cellular The ...
Plasma Cell Dyscrasias and Engineered Cellular Therapy: Is a Cure in Sight?
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The speaker reviews advances in multiple myeloma, a once rapidly fatal cancer whose survival has improved substantially with modern therapies. Diagnosis relies on CRAB features—high calcium, renal impairment, anemia, and bone lesions—or SLiM biomarkers that identify disease before organ damage. Treatment is tailored to fitness and transplant eligibility; transplant can deepen remission, particularly in high-risk disease, while maintenance therapy remains standard.<br /><br />The talk’s central focus is whether cellular immunotherapy could make myeloma curable. Minimal residual disease (MRD) testing detects very small amounts of cancer in bone marrow and is associated with better outcomes. The speaker describes a proposed cure definition: at least five years off treatment, with repeated negative marrow assessments and clear imaging. CAR T-cell therapy has produced deep, durable responses, including in heavily pretreated patients, and bispecific antibodies are also showing promise earlier in the disease course. These treatments may eventually reduce reliance on prolonged chemotherapy and possibly replace transplant.<br /><br />A case of a patient with advanced, treatment-resistant myeloma illustrates both CAR T-cell therapy’s potential and its serious complications. In discussion, the speaker notes that renal impairment does not rule out CAR T-cell therapy, though bispecific antibodies may be easier for some patients with fragile kidney function. MRD is increasingly used to guide treatment duration, but not yet routinely to justify treatment escalation.
Asset Caption
Hamza Hashmi, MD
Meta Tag
Speaker
Hamza Hashmi
Keywords
multiple myeloma
CRAB criteria
SLiM biomarkers
MRD testing
CAR T-cell therapy
bispecific antibodies
transplant eligibility
×
Please select your language
1
English